New York State Legislature Considers Ban on Flavored Nicotine Pouches

Feb.12.2025
New York State Legislature Considers Ban on Flavored Nicotine Pouches
New York State Legislature is considering a ban on flavored nicotine pouches to curb underage tobacco use.

According to a report by Timesunion on February 11, the New York State Legislature is considering passing a bill to ban the sale of flavored nicotine pouches in the state. The ban is based on the belief that fruit and candy flavored products are a marketing tactic aimed at minors.


Congresswoman Linda Rosenthal has expressed concerns about the nicotine pouch brand ZYN, which offers flavors such as mint, citrus, and coffee. She pointed out that with flavored e-cigarettes becoming harder to find in New York, minors may turn to nicotine pouches.


Brian Erkkila, the Chief Scientific Officer of Swedish Match, stated that the main customer base of ZYN is not new nicotine users, but rather adults who are transitioning to safer products.


However, some experts believe that a comprehensive ban on the product may backfire. Raymond Niaura, a professor at New York University, stated that data shows the proportion of teenagers using the product is still very low, and he believes a ban is an "overreaction." Alan Mathios, a professor at Cornell University, also warned that a ban on flavored nicotine pouches could lead to the emergence of an illegal market, making it easier for teenagers to access such products.


On January 17, the U.S. FDA approved marketing authorization for 20 ZYN brand nicotine pouch products. This marks a significant milestone for the FDA in regulating novel tobacco products.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives
France’s Top Administrative Court Suspends Nicotine Pouch Decree
France’s Top Administrative Court Suspends Nicotine Pouch Decree
France’s Council of State has suspended a government decree that was set to ban the manufacture, production and export of nicotine pouches from April 2026. The court ruled that companies were not given sufficient time to reorganise their operations. A final decision on the legality of the decree is expected by June 2026. The court noted that the commercial sale of nicotine pouches is already restricted under existing public health laws.
Dec.23 by 2FIRSTS.ai
Product | INNOKIN Launches Magnetic Open-System Device, Pod + Power Bank Design Debuts in UK and US Channels
Product | INNOKIN Launches Magnetic Open-System Device, Pod + Power Bank Design Debuts in UK and US Channels
INNOKIN has recently launched its new open-system e-cigarette, EZ LEVA, on its official website, and it is now available through online channels in the UK and the United States. Featuring a magnetic design, the device adopts a pod + power bank form factor. Its 400mAh (device) + 2000mAh (charging case) battery setup follows a similar configuration logic to comparable products such as the SMOK Airmate and KIWI 2.
Dec.09 by 2FIRSTS.ai
Study: TikTok Content Frames Nicotine Pouches as “Trendy Accessories,” Diluting Risk Perception Among Youth
Study: TikTok Content Frames Nicotine Pouches as “Trendy Accessories,” Diluting Risk Perception Among Youth
A study published in JMIR Formative Research analyzed 132 TikTok videos related to nicotine pouches and found that platform content predominantly presents these products as a “youthful trend” rather than as smoking cessation tools. Health risks are underrepresented, the user base appears largely male, and this portrayal may influence how adolescents perceive the risks associated with nicotine products.
Dec.04 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai
Product | 2Firsts Exclusive: Breaking Down Pachamama 25K, CHUC’s First U.S.-Made Factory Product
Product | 2Firsts Exclusive: Breaking Down Pachamama 25K, CHUC’s First U.S.-Made Factory Product
U.S. e-cigarette company Charlie’s has brought its first domestic manufacturing facility online, launching the disposable Pachamama 25K, which will initially roll out to 300 retail stores in Texas. The device features a 20 ml e-liquid capacity with 5% nicotine, three power modes and a built-in 1000 mAh battery, and is advertised to deliver up to 25,000 puffs.
Dec.02 by 2FIRSTS.ai